Show simple item record

dc.contributor.authorMuralidharan, Priya
dc.contributor.authorMallory, Evan K.
dc.contributor.authorMalapit, Monica
dc.contributor.authorPhan, Hanna
dc.contributor.authorLedford, Julie G.
dc.contributor.authorHayes, Don
dc.contributor.authorMansour, Heidi M.
dc.date.accessioned2022-04-06T01:30:00Z
dc.date.available2022-04-06T01:30:00Z
dc.date.issued2020
dc.identifier.citationMuralidharan, P., Mallory, E. K., Malapit, M., Phan, H., Ledford, J. G., Hayes, D., & Mansour, H. M. (2020). Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols. RSC advances, 10(68), 41846-41856.en_US
dc.identifier.doi10.1039/d0ra07203f
dc.identifier.urihttp://hdl.handle.net/10150/663891
dc.description.abstractRationale: lactose is the only FDA-approved carrier for dry powder inhaler (DPI) formulations in the US. Lactose carrier-based DPI products are contraindicated in patients with a known lactose allergy. Hence, inhaler formulations without lactose will benefit lactose allergic asthmatics. Objectives: to rationally design and develop lactose carrier-free dry powder inhaler formulations of fluticasone propionate and salmeterol xinafoate that will benefit people with known lactose allergy. The study also aims at improving the aerosol deposition of the dry powder formulation through advanced particle engineering design technologies to create inhalable powders consisting of nanoparticles/microparticles. Methods: advanced DPI nanoparticle/microparticle formulations were designed, developed and optimized using organic solution advanced closed-mode spray drying. The co-spray dried (co-SD) powders were comprehensively characterized in solid-state and in vitro comparative analysis of the aerodynamic performance of these molecularly mixed formulations was conducted with the marketed formulation of Advair (R) Diskus (R) interactive physical mixture. Measurements and main results: comprehensive solid-state physicochemical characterization of the powders showed that the engineered co-SD particles were small and spherical within the size range of 450 nm to 7.25 mu m. Improved fine particle fraction and lower mass median aerodynamic diameter were achieved by these DPI nanoparticles/microparticles. Conclusions: this study has successfully produced a lactose-free dry powder formulation containing fluticasone propionate and salmeterol xinafoate with mannitol as excipient engineered as inhalable DPI nanoparticles/microparticles by advanced spray drying. Further, co-spray drying with mannitol and using Handihaler (R) device can generate higher fine particle mass of fluticasone/salmeterol. Mannitol, a mucolytic agent and aerosol performance enhancer, is a suitable excipient that can enhance aerosol dispersion of DPIs.en_US
dc.description.sponsorshipNational Institute of Allergy and Infectious Diseasesen_US
dc.language.isoenen_US
dc.publisherRoyal Society of Chemistry (RSC)en_US
dc.rightsThis journal is © The Royal Society of Chemistry 2020. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/en_US
dc.titleAdvanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosolsen_US
dc.typeArticleen_US
dc.identifier.eissn2046-2069
dc.contributor.departmentUniv Arizona, Coll Pharmen_US
dc.contributor.departmentUniv Arizona, Dept Cellular & Mol Med, Coll Meden_US
dc.contributor.departmentUniv Arizona, Dept Med, Div Translat & Regenerat Med, Coll Meden_US
dc.contributor.departmentUniv Arizona, BIO5 Res Insten_US
dc.contributor.departmentUniv Arizona, Inst Environmen_US
dc.identifier.journalRSC Advancesen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleRSC Advances
dc.source.volume10
dc.source.issue68
dc.source.beginpage41846
dc.source.endpage41856
refterms.dateFOA2022-04-06T01:30:01Z


Files in this item

Thumbnail
Name:
d0ra07203f.pdf
Size:
2.078Mb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

This journal is © The Royal Society of Chemistry 2020. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.
Except where otherwise noted, this item's license is described as This journal is © The Royal Society of Chemistry 2020. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.